FDA Eases Monitoring Rules, Removes REMS from BMS Cell Therapies
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel;…
Read More...
Read More...
